Skip to Content

Data on VIVUS' Qnexa to be Presented at International Congress on Obesity

Update: Qsymia (phentermine/topiramate) Now FDA Approved - July 17, 2012


MOUNTAIN VIEW, Calif., July 12 /PRNewswire-FirstCall/ -- VIVUS, Inc. (NASDAQ:VVUS) today announced that data on Qnexa®, an investigational drug candidate, will be presented at the 11th International Congress on Obesity (ICO) in Stockholm, Sweden. Kishore Gadde, MD, director of obesity clinical trials at Duke University, will make an oral presentation, "Low-Dose, Controlled-Release Phentermine/Topiramate for Reduction of Weight, Related Risks in Overweight/Obese Adults With >= 2 Comorbidities," on Monday, July 12 at 2:45 PM CET.

David Allison, MD, professor and director of the Nutrition Obesity Research Center at the University of Alabama at Birmingham, will make a poster presentation, "Weight Loss at 56 Weeks in Obese Adults With Low-Dose, Controlled-Release Phentermine/Topiramate," on Wednesday, July 14, at 1:00 PM CET.

  Following are details about the upcoming presentations:

  11th International Conference on Obesity, Stockholm International Fairs
   & Congress Centre, Stockholm, Sweden

  Oral Presentation

  Date and Time: Monday, July 12, 2010 2:45-3:00 PM CET
  Presentation Title: Low-Dose, Controlled-Release Phentermine/
   Topiramate for Reduction of Weight, Related Risks in Overweight/Obese
   Adults With >=2 Comorbidities
  Session: Novel Pharmacological Approaches to Treat Obesity
  Abstract: T3:OS2.4
  Presenter: Kishore Gadde, M.D.

  Poster Presentation

  Date and Time: Wednesday, July 14, 2010 1:00-2:00 PM CET
  Presentation Title: Weight Loss at 56 Weeks in Obese Adults With Low-
   Dose, Controlled-Release Phentermine/Topiramate
  Abstract: T3:PO.03
  Presenter: David Allison, M.D.

  About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's lead product in clinical development, Qnexa®, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2009 and periodic reports filed with the Securities and Exchange Commission.


  VIVUS, Inc.              Investor Relations:    The Trout Group
  Timothy E. Morris                               Brian Korb
  Chief Financial Officer                         646-378-2923
                           Media Relations:       Pure Communications, Inc.
                                                  Dan Budwick

Source: VIVUS, Inc.

CONTACT: VIVUS, Inc., Timothy E. Morris, Chief Financial Officer,
+1-650-934-5200; Investor Relations: The Trout Group, Brian Korb,
+1-646-378-2923; or Media Relations: Pure Communications, Inc., Dan Budwick,

Web Site:

Posted: July 2010